Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12967745 | 0.81 | CYP2A6 (0.50) | LOXL2F2GAAPKMSIRT1 | |
| SCHEMBL12958646 | 0.81 | LOXL2 (0.50) | LOXL2F2GAAPKMSIRT1 | |
| SCHEMBL12803354 | 0.78 | LOXL2 (0.50) | LOXL2F2GAAPKMSIRT1 | |
| SCHEMBL31020832 | 0.77 | GAA (0.46) | LOXL2F2GAAPKMNPBWR1 | |
| Hydrochloric Acid SCHEMBL1111607 | 0.77 | GAA (0.46) | LOXL2F2GAAPKMNPBWR1 | |
| SCHEMBL1111547 | 0.77 | GAA (0.46) | LOXL2F2GAAPKMNPBWR1 | |
| SCHEMBL5792170 | 0.74 | F2 (0.61) | LOXL2F2GAAPKM | |
| SCHEMBL28414980 | 0.74 | LOXL2 (0.58) | LOXL2NR3C1PGRNR3C2 | |
| SCHEMBL1313330 | 0.74 | LOXL2 (0.46) | LOXL2 | |
| SCHEMBL12804457 | 0.73 | NR3C1 (0.50) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | LOXL2 4182/4885F2 4864/4885GAA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.